Dr. Miller’s exciting research in the field of neurodegenerative diseases consistently generates national and international interest.
NEALS Webinar: “C9: From ID (Identification) to Therapy”
Dr. Timothy Miller, Washington University, and Dr. Merit Cudkowicz, Massachusetts General Hospital, provide an update on the C9orf72 Natural History Study and discuss therapies in development for C9 patients.
Phase 1 Clinical Trial to Test BIIB067 in People with ALS Currently Recruiting Participants
MDA announces enrollment in the Phase I/II trial of SOD1 antisense oligonucleotides. Dr. Timothy Miller led the first trial of these SOD1 ASOs in ALS patients and is now the academic Principle Investigator for the Phase I/II trial, sponsored by Biogen Idec and Ionis Pharmaceuticals.
Genetic Mutations Linked to Higher Proportion of ALS Cases Than Previously Believed (Links to an external site)
New research indicating genetic mutations may underlie more ALS cases than scientists originally thought. Dr. Miller’s close colleague Dr. Matthew Harms states, “To our surprise, we found that 26 percent of sporadic ALS patients had potential mutations in one of the known ALS genes we analyzed. This suggests that mutations may be contributing to significantly more ALS cases.”
ALS Trial Shows Novel Therapy is Safe (Links to an external site)
Highlights the exciting new results from Dr. Miller’s first Phase I trial of SOD1-targeting ASOs, stating that the investigational treatment for inherited forms of ALS has passed an early clinical trial for safety.
Breakthrough ALS Research at Washington University (Links to an external site)
Dr. Miller featured in news article and video about his Phase I clinical trial of antisense oligonucleotides targeting the SOD1 protein in ALS patients with SOD1 mutations.
Video: 2011 MDA Telethon ALS Research Update
MDA presents an update regarding research on ALS, featuring Dr. Timothy M. Miller from Washington University in St. Louis. MDA is supporting a clinical trial of antisense therapy seeking to counteract the affects of a toxic version of the protein SOD1 in patients with an inherited form of ALS.
Video: 2010 MDA Telethon ALS Research Update
MDA presents an update regarding research on ALS, featuring Dr. Timothy M. Miller from Washington University in St. Louis.